D
Derek P. Chew
Researcher at Flinders University
Publications - 393
Citations - 21169
Derek P. Chew is an academic researcher from Flinders University. The author has contributed to research in topics: Myocardial infarction & Acute coronary syndrome. The author has an hindex of 60, co-authored 342 publications receiving 18879 citations. Previous affiliations of Derek P. Chew include Flinders Medical Centre & Auckland City Hospital.
Papers
More filters
Journal ArticleDOI
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
Marco Roffi,Carlo Patrono,Jean-Philippe Collet,Christian Mueller,Marco Valgimigli,Felicita Andreotti,Jeroen J. Bax,Michael A. Borger,Carlos Brotons,Derek P. Chew,Baris Gencer,Gerd Hasenfuss,Keld Kjeldsen,Patrizio Lancellotti,Ulf Landmesser,Julinda Mehilli,Debabrata Mukherjee,Robert F. Storey,Stephan Windecker +18 more
TL;DR: The current guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation are based on the findings of the ESC Task Force on 12 March 2015.
Journal ArticleDOI
Intravenous Platelet Blockade with Cangrelor during PCI
Deepak L. Bhatt,A. Michael Lincoff,C. Michael Gibson,Gregg W. Stone,Steven McNulty,Gilles Montalescot,Neal S. Kleiman,Shaun G. Goodman,Harvey D. White,Kenneth W. Mahaffey,Charles V. Pollack,Steven V. Manoukian,Petr Widimsky,Derek P. Chew,Fernando A. Cura,Ivan H Manukov,František Toušek,M. Zubair Jafar,Jaspal Arneja,Simona Skerjanec,Robert A. Harrington +20 more
TL;DR: The use of periprocedural cangrelor during PCI was not superior to placebo in reducing the primary end point, and the prespecified secondary end points of stent thrombosis and death were lower in the cang Relor group, with no significant increase in the rate of transfusion.
Journal ArticleDOI
Platelet Inhibition with Cangrelor in Patients Undergoing PCI
Robert A. Harrington,Gregg W. Stone,Steven McNulty,Harvey D. White,A. Michael Lincoff,C. Michael Gibson,Charles V. Pollack,Gilles Montalescot,Kenneth W. Mahaffey,Neal S. Kleiman,Shaun G. Goodman,Maged Amine,Dominick J. Angiolillo,Richard C. Becker,Derek P. Chew,William J. French,Franz Leisch,Keyur Parikh,Simona Skerjanec,Deepak L. Bhatt +19 more
TL;DR: Cangrelor was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 minutes before PCI, in reducing the composite end point of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours.
Journal ArticleDOI
[2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation].
Marco Roffi,Carlo Patrono,Jean-Philippe Collet,Christian Mueller,Marco Valgimigli,Felicita Andreotti,Jeroen J. Bax,Michael A. Borger,Carlos Brotons,Derek P. Chew,Baris Gencer,Gerd Hasenfuss,Keld Kjeldsen,Patrizio Lancellotti,Ulf Landmesser,Julinda Mehilli,Debabrata Mukherjee,Robert F. Storey,Stephan Windecker +18 more
TL;DR: The comparison of prasugrel at the time of Percutaneous Coronary Intervention or as Pretreatment at the Time of Diagnosis in Patients with Non-ST Elevation Myocardial Infarction was conducted by as mentioned in this paper.
Journal ArticleDOI
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes
Marco Roffi,Derek P. Chew,Debabrata Mukherjee,Deepak L. Bhatt,Jennifer White,Christopher Heeschen,Christian W. Hamm,David J. Moliterno,Robert M. Califf,Harvey D. White,Neal S. Kleiman,Pierre Theroux,Eric J. Topol +12 more
TL;DR: A meta-analysis of the diabetic populations enrolled in the 6 large-scale platelet GP IIb/IIIa inhibitor ACS trials investigated whether diabetic patients with ACS derive particular benefit from platelet glycoprotein (GP) IIb-IIIa receptor inhibition.